PECAM1 and persistent truncus arteriosus: Our experiments showed that KLX markedly prevented the upregulation of mesenchymal markers (vimentin and α-SMA) and the downregulation of endothelial-specific markers (CD31 and VE-cadherin) of the TAC mice, which indicates that KLX attenuates TAC-induced EndMT.